grant
Understanding viral mechanisms to inform oncolytic therapies for EBV-associated lymphomas in PLWH
Organization UNIVERSITY OF FLORIDALocation GAINESVILLE, UNITED STATESPosted 1 Jul 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY20250-11 years oldAIDSAIDS VirusAIDS lymphomaAIDS-Associated LymphomaAIDS-Related LymphomaAcquired Immune DeficiencyAcquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome VirusAffectAfricanAfrican Burkitt's lymphomaAfrican LymphomaApoptosis-Related Cysteine Protease Caspase 1B blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBZLF1BZLF1 geneBZLF1 proteinBasal Transcription FactorBasal transcription factor genesBindingBiologyBurkitt HerpesvirusBurkitt LymphomaBurkitt Lymphoma VirusBurkitt TumorBurkitt's Lymphoma/LeukemiaBurkitt's Type Small Non-Cleaved Cell LymphomaCASP-1CASP1CASP1 geneCancer CauseCancer EtiologyCancersCaringCaspase-1Caspase-1 GeneCause of DeathCell BodyCell FractionCell LineCellLineCellsCessation of lifeChemicalsChildChild YouthChildren (0-21)CountryDLBCLDNADNA MethylationDNA ReplicationDNA SynthesisDNA biosynthesisDNA mutationDNA-Binding ProteinsDeathDeoxyribonucleic AcidDiabetes MellitusDiffuse Large B-Cell LymphomaDisparateDrugsE1A Binding Protein p300EB virusEBVEBV associated lymphomaEBV encoded ZTAEBV induced lymphomaEBV latencyEBV lymphomaEBV lymphoma cellEBV(+) lymphomaEBV+ lymphomaEBV+ve lymphomaEBV-positive lymphomasEBV-related lymphomaEP300EP300 geneEconomic IncomeEconomical IncomeEndemic Burkitt's LymphomaEnsureEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelial CellsEpstein Barr VirusEpstein Barr Virus Associated LymphomaEpstein Barr Virus LymphomaEpstein Barr Virus driven lymphomaEpstein Barr Virus encoded ZTAEpstein Barr Virus lymphoma cellEpstein Barr induced lymphomaEpstein-Barr Virus latencyEpstein-Barr Virus-Related LymphomaEpstein-Barr virus BZLF1 proteinEpstein-Barr virus Zta proteinEventFacial BonesGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenomicsGlandular FeverHHV-4HHV4HIVHIV Associated LymphomaHIV LymphomaHIV-Related LymphomaHerpesviridaeHerpesvirusesHeterochromatinHuman Herpesvirus 4Human Immunodeficiency VirusesICE ProteaseIL-1 beta ConvertaseIL-1 beta-Converting EnzymeIL-1BCIL-1b Converting EnzymeIL1B-ConvertaseIL1BCIL1BCEImmuneImmunesIncomeIndividualInfectious MononucleosisInfectious Mononucleosis VirusInflammasomeInterleukin 1-B Converting EnzymeInterleukin 1-Beta ConvertaseInterleukin-1 Beta Converting EnzymeInterleukin-1 Converting EnzymeJawKAT3BKineticsKnowledgeLAV-HTLV-IIILearningLinkLymphadenopathy-Associated VirusLymphoma cellLyticLytic CycleLytic InfectionLytic PhaseLytic VirusMalignant CellMalignant NeoplasmsMalignant TumorMediatingMedicationModelingMolecular InteractionMutationNOMIDNeonatal Onset Multisystem Inflammatory DiseaseNon-Hodgkin's LymphomaNonhodgkins LymphomaOncolyticOralOutcomePatientsPersonsPharmaceutical PreparationsPhasePhase 1b/2 Clinical TrialPhase 1b/II Clinical TrialPhase Ib/II Clinical TrialPopulationPredispositionProteinsPublic HealthRNA ExpressionRefractoryResistanceSiteStrains Cell LinesSusceptibilityTXNIPTXNIP geneTestingTherapeuticThioredoxin-Binding Protein 2Thioredoxin-Interacting ProteinTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTranslatingTransplant RecipientsTumor CellVDUP1ViralViral GenomeVirusVirus-HIVVitamin D3-Upregulating Protein 1ZEBRA proteinZinc Finger DomainZinc Finger MotifsZinc FingersZta proteinZta transcription activatorantiretroviral therapyantiretroviral treatmentc mycc-myc Genescancer cellcell transformationchemotherapycmycco-repressorcorepressorcultured cell linederepressiondiabetesdrug/agentepigeneticallyepigenomeface bone structuregene co-repressorgene corepressorgenetic co-repressorgenetic corepressorgenome mutationglobal gene expressionglobal transcription profileherpes virushistone acetyltransferase p300improvedimproved outcomeincomeskidslarge cell Diffuse non-Hodgkin's lymphomamalignancymononucleosismortalityneoplasm/cancerneoplastic cellnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnon-Hodgkins diseasenovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachnucleoside analogoncolysisossa facieip300pathogenpredictive signaturepromoterpromotorprotein complexrecruitresistantresponsesuccesstooltranscription factortranscriptometransformed cellstransplant patienttumorv-myc Avian Myelocytomatosis Viral Oncogene Cellular Homologvirus genomeyoungster
Description preview
PROJECT SUMMARY
Non-Hodgkin lymphomas are a common cause of cancer-related death in people living with HIV (PLWH).
Remarkably, despite advances in chemotherapy and antiretroviral therapy, HIV-infected individuals with Epstein-
Barr virus (EBV)+ diffuse large B cell lymphoma (DLBCL) suffer from worse overall survival compared to those
with EBV-…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click